H
ealth care spending was a major topic of the 2012 presidential race and promises to remain in the spotlight as the United States addresses the need to cut spending in the face of the federal deficits in 2013 and beyond. In 2013, health care expenditures are expected to grow 3.82%, reaching $2915.5 billion, or 17.8% of the gross domestic product. 1 While this rate of growth was slightly lower than that in 2012, by 2014, major coverage expansions mandated in the Patient Protection and Affordable Care Act are expected to drive growth by 7.4% (to $3130.2 billion). This will result in a greater proportion of national health care expenditures being paid by the federal government (30% in 2014). This growth in federal spending on health care combined with the current focus on federal debt and deficit reduction may result in meaningful changes to Medicare and other key health care programs.
mix (-8.4% ). For the 9 months ending in September 2012, total prescription expenditures grew 2.7% when compared with the same period in 2011. Oncology products remained important expenditures for hospitals and clinics. Antineoplastic agents were the top medication class for expenditures in nonfederal hospitals, and oncology products accounted for 32.2% of drug expenditures in the clinic setting in the first 9 months of 2012. Conclusion. For 2013, we project a 1-3% increase in total drug expenditures across all settings, a 2-4% increase in expenditures for clinic-administered drugs, and a 0.5% decline to 1.5% increase in hospital drug expenditures. Health-system pharmacy leaders should carefully examine their own local drug-utilization patterns to determine their own organization's drug expenditure forecast. Am J Health-Syst Pharm. 2013; 70:In Press spending. Increased utilization and access to drugs attributable to the increased aging population and expanded insurance coverage, along with the launch of new and expensive medications, are the primary factors raising drug expenditures, while patent expirations and the availability of less-expensive generic products are the primary factors reducing drug expenditures. 2 This article discusses factors likely to influence drug expenditures, describes drug expenditure trends in 2012, and projects drug expenditures for 2013. Our intent is to provide information and analysis that will aid health-system pharmacy executives and other health-system leaders who are responsible for developing hospital and clinic drug budgets in determining how future changes in medication use will affect drug expenditures in their own institutions. We examined trends in pharmaceutical expenditures, both generally and by setting (with an emphasis on nonfederal hospitals and clinics), that may help predict expenditures in 2013. We also examined other factors that may influence future pharmaceutical expenditures, including new drugs and newly available generics. Finally, drug expenditures by sector (total, hospital, and clinic settings) for 2013 were projected.
Methods
Our forecast of pharmaceutical expenditures in 2013 was based on examination of both historical trends in drug expenditures and expected changes in the drug marketplace that may influence drug expenditures in hospitals and clinics, including recent drug approvals and expected patent expirations. First, we analyzed prescription drug expenditures in 2011 through September 2012. Data for this analysis were obtained from the IMS Health National Sales Perspectives (NSP) database. 3 NSP is a statistically valid projected audit that describes 100% of the sales in every major class of trade and distribution channel for prescription pharmaceuticals, nonprescription products, and select self-administered diagnostic products in the United States, measuring both unit volume and invoice dollars. The NSP sample is derived from over 1.5 billion annual transactions from over 100 pharmaceutical manufacturers and more than 700 distribution centers. As of September 2012, NSP tracked sales into 5,789 nonfederal hospitals, 145,812 clinics, 59,674 retail pharmacies, 323 mail-service pharmacies, 5,050 home health facilities, and 3,307 long-term-care outlets, in addition to thousands of other entities. All data from NSP were used in the analysis (e.g. nonsystemic formulations were used), and drug class groupings were based on IMS Health's proprietary Uniform System of Classification. 4 When examining drug expenditures, we reported total dollars spent as well as growth, the latter being the percentage change (increase or decrease) in expenditures from one period to the next. We categorized the factors that drive changes in pharmaceutical expenditures as (1) new products, (2) price inflation, and (3) volume and mix. The "new products" category represents growth in expenditures attributable to products that were not on the market in the comparison time period (i.e., previous year). Growth in prescription drug expenditures attributable to price inflation refers to changes in the unit cost of drugs that were previously on the market in the comparison time period (i.e., the change in price from one year to the next). Last, the "volume and mix" category combines changes in volume of utilization of existing products (i.e., changes in the number of users, number of days of therapy, or number of doses of therapy per day) and changes in usage patterns (i.e., from one product to another). An example of mix is when prescribing moves from brand to generic products, resulting in reduced expenditures. Additional analyses were conducted focused on oncology therapies because of the importance of these therapies to overall drug expenditures. The proportions of expenditures incurred in retail settings, mail-order pharmacies, long-term-care facilities, health maintenance organizations, nonfederal facilities, federal facilities, and clinics between 2007 and 2012 were estimated separately for oral and injectable oncology agents to examine shifts in distribution channel for these products.
Recent drug approvals and drugs in development were reviewed, since these often increase drug expenditures. Drugs and biological agents anticipated to be approved by the Food and Drug Administra-tion (FDA) in 2013 were identified by searching pharmaceutical and biotechnology business news for articles of interest to investors in the industry. Once products were identified, their Prescription Drug User Fee Act (PDUFA) dates were determined by examining information in official press releases by the respective companies sponsoring the drugs or biological agents. If no explicit PDUFA date was mentioned in the official press release, the date was extrapolated by adding a 6-month (for priority reviews) or 10-month time frame (for standard reviews) to the new drug application (NDA) or biological license application (BLA) submission date. Drugs or biologicals that had negative FDA committee reviews at the time this article was prepared were not included. In addition, agents with FDA-approved labeling for other indications (without major differences in drug delivery) were also excluded.
Pharmaceuticals anticipated to lose patent protection were reviewed to estimate their impact on drug expenditures. Drugs and biologicals whose patent protection is expected to end in 2013 or the first quarter of 2014 were identified from several sources. 2, 5, 6 and confirmed by searching business news for articles of interest to investors in the pharmaceutical and biotechnology industry. The list of potential future patent expirations provided in the 2012 forecast 2 was examined to determine if these agents were delayed or expected to lose patent protection during 2013 or the first quarter of 2014. The list of potential patent expirations was further limited to pharmaceuticals that represent substantial expenditures for the entire market or those that are particularly important to the hospital or clinic setting.
Finally, we projected drug expenditure growth in 2013 for nonfederal hospitals, clinics, and all sectors. These estimates were generated through a combination of quantitative and qualitative analyses and our opinions. An analysis of past expenditure patterns using linear leastsquares regression was performed to estimate 2013 expenditures in the absence of major changes. We also developed qualitatively based estimates of growth, considering major factors that are believed to influence future drug expenditures, as discussed in this article. Projections from other sources were also examined. Once we evaluated these estimates, consensus regarding anticipated drug expenditure growth rates for 2013 was reached. in mail-order pharmacies (5.5%), followed by federal facilities (4.1%). Clinics experienced 3.1% growth. Sectors with decreased expenditures were long-term-care facilities (-4.7%), retail pharmacies (-0.8%), and nonfederal hospitals (-0.4%). While retail pharmacies experienced a slight decrease in drug expenditures, this was offset by increases in mail-order pharmacies and reflects an ongoing shift between these channels.
Results

Historical
A pattern of increased expenditures due to greater use of new products and increased prices of existing products, combined with decreased expenditures from reduced overall volume and mix, was consistent across all sectors except clinics. While clinics experienced an overall 3.1% increase in expenditures, there were Over the past five years, there has been a considerable shift in the distribution of spending for oral oncology agents by setting (Figure 2) . 3 In the 12 months ending in September 2007, 28% of spending on oral oncology agents was through mail-order pharmacies, while 58% was through retail pharmacies. However, for the 12 months ending in September 2012, 57% of the spending for oral oncology agents was through mailorder pharmacies, while only 27% was through retail pharmacies. There was no such shift in spending observed for injectable oncology agents. In both 2007 and 2012, 72% of the spending for injectable oncology drugs was incurred in the clinic setting, and 23% of the spending was incurred in the hospital setting.
The top 15 products based on expenditures during the first nine months of 2012 in the nonfederal hospital setting are listed in Table 5 . For the nine-month period ending September 30, 2012, the top 3 hospital drugs in terms of expenditures were immune globulin, infliximab, and rituximab. Immune globulin maintained the top spot on the list despite a 20.5% decrease in expenditures compared with the same period in 2011. Of the agents included in this list, enoxaparin experienced the largest decline in expenditures expenditures. Antineoplastics were followed by hemostatic modifiers (11.5% of total) and antiinfectives (9.2% of total). The class with the largest change from 2011 to 2012 was hospital solutions, declining 13.4%, followed by hemostatic modifiers which decreased by 10.6%. Gastrointestinal agents grew the most (9.7% compared with 2011).
Recent drug approvals. Select novel agents that may receive FDA approval in the United States by the end of 2013 are listed in Table  7 , along with FDA review deadlines under the PDUFA. The PDUFA date is the deadline by which FDA must make a decision on a drug's application (this may be a decision to approve or not approve a drug) after a defined period of review. 28 Currently, the review period is 10 months for a standard review or 6 months for a priority review, after the manufacturer submits an NDA.
As shown in Table 8 , oncology drugs constitute many newly approved agents. For example, compared with 2011, there was a dramatic increase in the number of new molecular entities approved by FDA to treat oncological disorders in 2012; 13 agents were approved in 2012 versus 6 in 2011. The approximate cost for 28 days of therapy, based on the average wholesale price listed in Redbook Online, is presented in Table 8 . 29 For drugs that are dosed based on body weight or body surface area, standards of 70 kg and 1.73 m 2 , respectively, were used. In November 2012, Sanofi announced that it would cut the price of the drug ziv-aflibercept by half (not reflected in this table) amid criticism that the drug was too expensive. 30 As in the past, many new oncology agents are oral dosage forms (e.g., axitinib, bosutinib, cabozantinib, enzalutamide, ponatinib, regorafenib, vismodegib); thus, they are unlikely to significantly impact hospital or clinic expenditures because they are not usually initiated during a patient's hospital stay or administered by a practitioner in the outpatient clinic setting. Health systems with a modest-to-large oncology service line should plan for an increase in expenditures from the use of both ziv-aflibercept and pertuzumab. 31, 32 These agents are considered addons to existing therapeutic options for the treatment of high-incidence cancers. Institutions may see higher usage rates of pertuzumab, because it is an add-on to established firstline options for patients with metastatic, human epidermal receptor-2-positive breast cancer. The impact of the other novel injectable antineoplastic agents on an institution's expenditures will depend on the volume of patients being treated for multiple myeloma (carfilzomib), chronic myeloid leukemia (omacetaxine), and acute lymphocytic leukemia (liposomal vincristine). Larger tertiary institutions that routinely use high-dose methotrexate should prepare for the use of glucarpidase to increase inpatient drug expenditures, but the use of this therapy is unpredictable.
Patent expirations. The growing availability and subsequent rapid use of generic drugs continue to have a substantial moderating influence on prescription drug expenditures. Compared with 2012, fewer blockbuster drugs (annual sales of more than $1 billion) are expected to lose patent protection in 2013. Key products that may face generic competition in the coming year based on various sources are listed in Table 9 . 5 Several agents that were blockbuster drugs or those that occupy therapeutic niches have recently lost patent protection: atorvastatin, clopidogrel, escitalopram, montelukast, pioglitazone, quetiapine, and oral vancomycin. These newly available generic agents are expected to have a significant impact on expenditures in the outpatient setting, though some savings may be realized by hospitals as well. Expenditures on generic noninjectables (not including branded generics) in the retail pharmacy setting increased by 19.7% for the year through September 2012, with volume and mix (3.0% increase) and use of newly available products (22.1% increase) contributing to the increase, despite a reduction in price of 5.4% during that time. A similar increase (21.9%) in the sale of these agents occurred in nonfederal hospitals; however, noninjectable agents accounted for only 28.6% of expenditures in this setting compared with 91.7% of expenditures in the retail setting. 3 While a generic version of the sildenafil formulation used to treat pulmonary hypertension (Revatio, Pfizer) became available in 2012, a key patent for the formulation used to treat erectile dysfunction was upheld, and generic availability of this agent is not expected until 2020.
Two blockbuster drugs, fenofibrate and duloxetine, are projected to lose patent exclusivity in 2013 (Table  9) . 5 Several additional high-cost agents (e.g., extended-release niacin, rabeprazole) are also expected to lose patent protection during that time. While this is fewer than the number of blockbuster agents that lost exclusivity during 2012, significant savings are expected to be realized through the reduced price of these agents. The release of generic fenofibrate is especially interesting due to changes made by the manufacturer of brand-name fenofibrate, who has reformulated the product multiple times and gained additional patent Although the majority of expenditures for these four agents (fenofibrate, duloxetine, extended-release niacin, and rabeprazole) occur in the community setting, these agents were responsible for $67.4 million in expenses for nonfederal hospitals in the first nine months of 2012. 3 The majority of these expenditures were for duloxetine ($51.0 million). The availability of numerous genericproducing competitors could result in significant reductions in expenditures across all settings, though lim- PDUFA date extrapolated based on new drug application submission date and review status (i.e., 10 months for standard review and 6 months for priority review) or specified data provided when available.
ited impact is expected in 2013 due to the 180-day exclusivity period provided to the first generic competitor.
In addition, generic availability of two angiotensin II receptor blockerscandesartan and valsartan-as well as rizatriptan for migraines, was anticipated by the end of 2012; however, all have been delayed. 5 The patent for brand-name valsartan expired in September 2012; however, at the time of writing, Ranbaxy has yet to release its generic valsartan product.
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Drug expenditure forecast for 2013. Several groups provide analysis and projections of trends in drug expenditures, and a comparison of these projections is provided in Table  10 . 1, 35 As with our forecast, these estimates were generated through both qualitative analysis of current and future drivers of pharmaceutical expenditures and quantitative analysis of past and current expenditure patterns. It is important to note differences in the projections provided by various sources. The Centers for Am J Health-Syst Pharm-Vol 70, 2013
Medicare and Medicaid Services reports and projects overall expenditures for all settings. Medco-Express Scripts reports trends and projections in traditional and specialty medications, not the sector in which those medications are purchased.
We developed qualitative estimates of growth in nonfederal hospitals, clinics, and all sectors combined for 2013, considering a number of factors that will influence future drug expenditures. First, as described above, recent expenditure trends have shown significantly lower growth than in previous decades. In all sectors combined and in the hospital sector, continued generic competition for widely used drugs should moderate expenditure increases. Although fewer blockbuster agents will lose patent protection in 2013 than in 2011 and 2012, 2013 will represent the first full year of widespread generic competition (i.e., after the expiration of the 180-day exclusivity period) for many of the agents approved in 2011 and 2012.
While significant changes resulting from the Patient Protection and Affordable Care Act may be noted in the future, the only element expected to affect pharmaceutical expenditures in the coming year is the mandate to cover contraceptive prescription drugs, which is not expected to have a significant effect on drug expenditures. In 2014, coverage of preexisting conditions will be expanded, and the individual mandate to carry a minimum level of health insurance will be required. This is likely to influence prescription drug expenditures in 2014 and beyond.
Based on the expenditure trends, new drug approvals, and patent expirations described above, we estimate an increase of 1-3% in expenditures overall (all sectors combined). We expect that expenditures for clinicadministered drugs will increase by 2-4%. For the hospital setting, we project a decrease of -0.5% to an increase of 1.5% for 2013.
Discussion
Emerging health care trends, including the continued implementation of health care reform, expansion of accountable care organization development, efforts to reimburse providers on the basis of improving performance, and the growing consolidation of health care into integrated health systems, are rapidly changing health care delivery in the United States. These substantial and fundamental changes make it essential for health-system pharmacy executives and other leaders to develop financial plans and budgets for prescription drug expenditures as accurately as possible. Over the past several years, we have cautioned readers to not use our financial projections as "multipliers" to calculate future expenditure levels in their health systems.
2,36-38 Instead, as described previously and in ASHP guidelines, local data must be carefully and systematically incorporated into an organization's drug expenditure forecast, as well as the external trends relevant to drug expenditures described in this article. 39, 40 This advice has never been more important than it is today. As health systems expand and become more highly integrated, health-system pharmacy leaders must embrace the pharmacy enterprise concept to improve patient care, align with health care reform, and effectively manage prescription drug expenditures. 41 Leaders who take the pharmacy enterprise approach will be positioned to manage medication use and expenditures across the continuum of care. The data presented in Figure 2 that show the dramatic shift in spending on oral oncology agents over five years from the retail pharmacies to the mail-order setting illustrate how essential it is to monitor shifts in drug expenditures. Because IMS Health does not have a separately defined and maintained channel for drugs from specialty pharmacies, the mailorder pharmacy category also reflects anticancer agents mailed from specialty pharmacies. Therefore, the growth of specialty pharmacy may be the cause of this channel shift, and pharmacy leaders must proactively monitor and plan a strategy for specialty pharmaceuticals for cancer and patients with other diseases. 42, 43 Beyond drug use and expenditures, pharmacy leaders must take a proactive approach to staying aware of developments in health policy, health finance, technology, and practice in order to respond to new phenomena in a confident and thoughtful manner. Even the most assiduously developed, strategic, tactical, and financial plans must remain flexible to accommodate unexpected events; changes that are known to be on the horizon must be considered in order to be responsive to unexpected events.
Besides broader trends in health care and pharmacy, this article includes key information to help guide planning for pharmaceuticals. Another resource that has recently been published and that provides additional guidance must also be read and understood by health-system pharmacy leaders: "Pharmacy Forecast 2013-2017: Strategic Planning Advice for Pharmacy Departments in Hospitals and Health Systems." 44 The report summarizes the results of a survey exploring eight domains in which emerging trends are likely to challenge pharmacy practice leaders. It also includes recommendations to guide planning in pharmacy departments. We strongly urge readers to review and use this report in financial and strategic planning. The complete report is freely available at www.ashpfoundation.org/ pharmacyforecast.
Our projections focus on factors likely to influence prescription drug expenditures in 2013, but pharmacy leaders should carefully monitor other developments that are expected to influence prescription drug expenditures beyond 2013, including the continuing implementation of the approval pathway for biosimilars and actions to facilitate the introduction of generic drugs.
Biological agents are essential but often expensive therapies; they are well represented on the list of top clinic (oncology and non-oncology) expenditures. An opportunity for decreasing hospital and health-system costs exists with biosimilars, which are copies of biological agents (not manufactured by the original, in- 45 Although a number of unresolved issues remain, further details of the regulatory process to implement approval of biosimilars through the BPCI Act became available when FDA released a series of draft guidances on biosimilars in early 2012. 46 These guidances provide information related to scientific considerations when demonstrating biosimilarity and on quality considerations when developing biosimilars. These documents also state that a biosimilar agent's label will contain information explicitly stating whether the product is deemed to be interchangeable with the reference product. Because biosimilars are not a new concept in Europe, the processes proposed by FDA can be compared with regulations established by the European Medicines Agency. Legislation first established a European biosimilar approval pathway in 2004, and the first biosimilar product was approved in 2006. 47, 48 Future development of the biosimilar pathway in the United States is expected to continue to draw on the European biosimilar experience.
Projections of Changes in Drug Expenditures
An alternative pathway for noninnovator biological products to reach the market is through completing a full development program and submitting a new BLA. This approach has been taken for a new granulocyte colony-stimulating factor product, tbo-filgrastim (Teva), which was approved by FDA in 2012. 49 Because the product was approved through a full BLA, this product is not biosimilar to the innovator filgrastim product (Neupogen, Amgen), and when approval of the product was announced, FDA made it clear that the product is not a biosimilar. The manufacturer of tbo-filgrastim announced that the earliest the product will be available is November 2013; therefore, the product does not represent a significant opportunity for cost savings in 2013. 50 However, approval of this noninnovator biological agent and release of the draft FDA guidance for biosimilars represent substantive progress toward competition and subsequent savings for expensive biological products. Pharmacy leaders should continue to carefully monitor biosimilar developments over the next several years.
The introduction of generic medications can be slowed when the innovator company pays generic manufacturers to delay introduction of their generic product ("pay to delay"). While legislation barring such arrangements has not progressed through Congress, significant action related to pay-for-delay agreements has occurred over the past year. The U.S. Court of Appeals for the Third Circuit ruled in July 2012 that pay-for-delay agreements between pharmaceutical manufacturers are anticompetitive. 51 The Federal Trade Commission has requested that the Supreme Court review a different case regarding a pay-for-delay arrangement between Abbott Laboratories and three generic manufacturers. 52 Final action in these cases will influence the speed at which first-time generic products become available.
Our forecast has several limitations. The primary source of our drug expenditure trend data was IMS Health NSP data through the end of September 2012, but expenditure patterns may change in the last quarter of 2012. This may be especially important for drugs that have seasonal fluctuations in utilization, like antimicrobials. IMS Health has a robust process to review, verify, and update data; therefore, data may be revised in the future, which could influence trend data and our projections. Empirical computation of the expected change in expenditures is limited, and the forecast projections were decided after carefully analyzing key trends. Further, we relied on reviews of key trends from various sources, but some important trends may have been missed. Due to these limitations, our forecasts are expressed in ranges, reflecting our uncertainty of the data analyzed.
Conclusion
For 2013, we project a 1-3% increase in total drug expenditures across all settings, a 2-4% increase in expenditures for clinic-administered drugs, and a 0.5% decline to 1.5% increase in hospital drug expenditures. Health-system pharmacy leaders should carefully examine their own local drug-utilization patterns to determine their own organization's drug expenditure forecast.
